Reimbursement Review Reports

( Last Updated : October 1, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Lynparza Olaparib metastatic castration-resistant prostate cancer (mCRPC) Active
Kineret anakinra Still's disease Withdrawn
Keytruda and Lenvima pembrolizumab and lenvatinib Advanced endometrial cancer Withdrawn
TBC etonogestrel Prevention of pregnancy Withdrawn
Tecentriq Atezolizumab Withdrawn
Keytruda Pembrolizumab
Admelog Insulin lispro Cancelled
Iluvien fluocinolone acetonide Diabetic macular edema (DME) Withdrawn
Ikervis cyclosporine keratitis, severe Withdrawn
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn